Truncation of the deubiquitinating domain of CYLD in myelomonocytic cells attenuates inflammatory responses

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Tsagaratou, Ageliki ^a,b   Kontoyiannis, Dimitris L ^b   Mosialos, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYLINDROMATOSIS TUMOR SUPPRESSOR PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CYLD PROTEIN, MOUSE; CYSTEINE PROTEINASE; LIPOPOLYSACCHARIDE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL LINEAGE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE FUNCTION; GENE LOCUS; GENE MUTATION; GENE TARGETING; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; MOUSE; MYELOMONOCYTIC CELL; NONHUMAN; UBIQUITINATION; ANIMAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; ENZYMOLOGY; IMMUNITY; MACROPHAGE ACTIVATION; PERITONEUM MACROPHAGE; SEPTIC SHOCK;

MUS;

ANIMALS; CYSTEINE ENDOPEPTIDASES; IMMUNITY; INFLAMMATION; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MICE; MONOCYTES; SHOCK, SEPTIC; UBIQUITINATION;

EID: 79251612497     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016397     Document Type: Article

References (23)

1. Massoumi R (2010) Ubiquitin chain cleavage: CYLD at work. Trends Biochem Sci 35: 392-399.
2. Sun SC (2010) CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 17: 25-34.
3. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R (2006) Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 125: 665-677.
4. Zhang J, Stirling B, Temmerman ST, Ma CA, Fuss IJ, et al. (2006) Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J Clin Invest 116: 3042-3049.
5. Lim JH, Ha UH, Woo CH, Xu H, Li JD (2008) CYLD is a crucial negative regulator of innate immune response in Escherichia coli pneumonia. Cell Microbiol 10: 2247-2256.
6. Lim JH, Stirling B, Derry J, Koga T, Jono H, et al. (2007) Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity 27: 349-360.
7. Reiley WW, Zhang M, Jin W, Losiewicz M, Donohue KB, et al. (2006) Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat Immunol 7: 411-417.
8. Kolls JK (2007) Balancing mucosal immunity: caught between CYLD and Charybdis. Immunity 27: 187-189.
9. Trompouki E, Tsagaratou A, Kosmidis SK, Dolle P, Qian J, et al. (2009) Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation. Neoplasia 11: 469-476.
10. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I (1999) Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 8: 265-277.
11. Tsagaratou A, Trompouki E, Grammenoudi S, Kontoyiannis DL, Mosialos G (2010) Thymocyte-specific truncation of the deubiquitinating domain of CYLD impairs positive selection in a NF-kappaB essential modulator-dependent manner. J Immunol 185: 2032-2043.
12. Cao S, Zhang X, Edwards JP, Mosser DM (2006) NF-kappaB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J Biol Chem 281: 26041-26050.
13. Carmody RJ, Ruan Q, Palmer S, Hilliard B, Chen YH (2007) Negative regulation of toll-like receptor signaling by NF-kappaB p50 ubiquitination blockade. Science 317: 675-678.
14. Timmer AM, Nizet V (2008) IKKbeta/NF-kappaB and the miscreant macrophage. J Exp Med 205: 1255-1259.
15. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA (2001) Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 7: 1291-1297.
16. Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, et al. (2007) NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 130: 918-931.
17. Kurihara T, Warr G, Loy J, Bravo R (1997) Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J Exp Med 186: 1757-1762.
18. Mellinghoff I, Daibata M, Humphreys RE, Mulder C, Takada K, et al. (1991) Early events in Epstein-Barr virus genome expression after activation: regulation by second messengers of B cell activation. Virology 185: 922-928.
19. Gao J, Huo L, Sun X, Liu M, Li D, et al. (2008) The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem 283: 8802-8809.
20. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, et al. (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424: 793-796.
21. Reiley WW, Jin W, Lee AJ, Wright A, Wu X, et al. (2007) Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J Exp Med 204: 1475-1485.
22. Jin W, Reiley WR, Lee AJ, Wright A, Wu X, et al. (2007) Deubiquitinating enzyme CYLD regulates the peripheral development and naive phenotype maintenance of B cells. J Biol Chem 282: 15884-15893.
23. Katsanou V, Papadaki O, Milatos S, Blackshear PJ, Anderson P, et al. (2005) HuR as a negative posttranscriptional modulator in inflammation. Mol Cell 19: 777-789.